Group 1 - The final issue price for the H-shares is set at HKD 86.40, which is at the upper limit of the price range of HKD 69.88 to HKD 86.40 [1] - The total number of shares issued is 11,500,000 H-shares, with 1,150,000 shares for the Hong Kong offering and 10,350,000 shares for the international offering, with no over-allotment option [1] - The total amount raised is HKD 994 million, with a net amount of HKD 940 million [1] Group 2 - The Hong Kong offering accounts for 10.00% of the total shares offered, while the international offering accounts for 90.00% [1] - The cornerstone investor is HARVEST INTERNATIONAL PREMIUM VALUE (SECONDARY MARKET) FUND SPC, which subscribed for 1,981,700 H-shares, representing 17.23% of the total issuance [1] - The underwriting team includes Huatai International, Guozhen International, Futu Securities, Xingzheng International, Minyin Capital, and ZTSC Zhongtai International [1]
海西新药（2637）获基石投资青睐，拟于2025年10月20日上市